Abstract
Background: Two mRNA COVID-19 vaccines, Pfizer-BioNTech and Moderna, are currently approved in the United States, and one viral-vector vaccine, J&J/Janssen, is authorized for limited use. The Vaccine Adverse Event Reporting System (VAERS) database gathers reports of adverse effects, including anaphylaxis. Objective: In this manuscript, we provide a summary of reported incidence of anaphylaxis rates following administration of the two mRNA and one viral-vector COVID-19 vaccine. Methods: A detailed investigation of the relative risk of anaphylaxis for recipients with or without a prior history of allergy and/or anaphylaxis is also described. Results: Overall reported incidence of anaphylaxis is 4.49 [95% CI: 0.25 – 8.73] cases per million doses administered. Conclusion: The reported risk of anaphylaxis is 1.83 times greater for recipients with prior allergies and no anaphylaxis but 17.70 times greater for recipients with prior allergies and anaphylaxis.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
